Stress cardiomyopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:45 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Stress cardiomyopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Levosimendan and Glucose Monohydrate for Patients with Low Ejection Fraction Takotsubo Syndrome https://clinicaltrials.eu/trial/study-of-levosimendan-and-glucose-monohydrate-for-patients-with-low-ejection-fraction-takotsubo-syndrome/ Wed, 29 Apr 2026 15:03:28 +0000 https://clinicaltrials.eu/trial/study-of-levosimendan-and-glucose-monohydrate-for-patients-with-low-ejection-fraction-takotsubo-syndrome/ This clinical trial is focused on studying a condition known as Takotsubo syndrome, which is a temporary heart condition often triggered by stress. The study is investigating the effects of a treatment called Levosimendan, which is a medication that helps the heart pump more effectively. The trial will compare the effects of Levosimendan to a placebo to see if it can help patients recover heart function more quickly and reduce the risk of future heart-related problems.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The main goal is to see if Levosimendan can improve the heart’s ability to pump blood during the hospital stay and reduce the chances of serious heart events, such as heart failure or stroke, over the next year.

The study will follow participants for a period of time to monitor their heart health and any potential side effects. By comparing the outcomes of those receiving Levosimendan with those receiving a placebo, researchers hope to determine the effectiveness of this treatment for people with Takotsubo syndrome and a low heart pumping ability, known as low ejection fraction.

]]> Study on the Effects of Cyclosporine A in Patients with Takotsubo Syndrome https://clinicaltrials.eu/trial/study-on-the-effects-of-cyclosporine-a-in-patients-with-takotsubo-syndrome/ Wed, 29 Apr 2026 15:00:01 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-cyclosporine-a-in-patients-with-takotsubo-syndrome/ This clinical trial is focused on studying a condition known as Takotsubo syndrome, which is a temporary heart condition often triggered by stress. The study will evaluate the effectiveness of a medication called Cyclosporine A (also known as CsA) compared to a placebo. Cyclosporine A is a medication that is commonly used to prevent organ rejection after transplants and to treat certain inflammatory conditions.

The purpose of the study is to determine if Cyclosporine A can reduce heart muscle damage in patients with Takotsubo syndrome. Participants in the study will receive either Cyclosporine A or a placebo, in addition to their standard medical care. The study will monitor the levels of a specific protein in the blood, known as Troponin T, which is an indicator of heart muscle damage. This will help researchers understand if the treatment is effective in reducing damage to the heart.

Throughout the study, participants will undergo regular assessments to measure changes in their heart condition and overall health. These assessments will include monitoring Troponin T levels at various time points and evaluating heart function through imaging techniques. The study aims to provide valuable insights into the potential benefits of Cyclosporine A for patients with Takotsubo syndrome, with the hope of improving treatment options for this condition in the future.

]]> Study on Beta-Blockers for Patients with Takotsubo Syndrome: Evaluating Selective, Non-Selective, and Alpha-Beta Blocking Agents https://clinicaltrials.eu/trial/study-on-beta-blockers-for-patients-with-takotsubo-syndrome-evaluating-selective-non-selective-and-alpha-beta-blocking-agents/ Wed, 29 Apr 2026 14:47:48 +0000 https://clinicaltrials.eu/trial/study-on-beta-blockers-for-patients-with-takotsubo-syndrome-evaluating-selective-non-selective-and-alpha-beta-blocking-agents/ This clinical trial is focused on studying Takotsubo Syndrome, an acute heart condition. The study will explore the effectiveness of different types of medications known as beta-blockers. These medications are commonly used to help the heart function better. The trial will include three types of beta-blockers: selective beta-blockers like nebivolol and metoprolol, non-selective beta-blockers such as propranolol, and beta-blockers with alpha activity like carvedilol. These medications are taken orally, meaning they are swallowed in pill form.

The purpose of the study is to evaluate how well these beta-blockers help the heart recover in patients with Takotsubo Syndrome. The study will last for up to 24 weeks, during which participants will receive one of the beta-blockers or a placebo. The main focus will be on observing the improvement in heart function using a test called an echocardiogram, which uses sound waves to create images of the heart. This will help doctors see how well the heart is pumping blood.

Throughout the study, the effects of the treatment will be monitored to see if there are any changes in heart function and to check for any side effects. The results will help determine the best treatment approach for patients with Takotsubo Syndrome, aiming to improve their heart health and overall well-being.

]]> Study on the Effects of Adenosine, Dipyridamole, and Apixaban in Patients with Takotsubo Syndrome https://clinicaltrials.eu/trial/study-on-the-effects-of-adenosine-dipyridamole-and-apixaban-in-patients-with-takotsubo-syndrome/ Wed, 29 Apr 2026 14:25:05 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-adenosine-dipyridamole-and-apixaban-in-patients-with-takotsubo-syndrome/ This clinical trial is focused on studying a condition known as , often referred to as “broken heart syndrome.” This condition can cause temporary heart muscle weakness, leading to symptoms similar to a heart attack. The study aims to explore the effects of different treatments on patients with this syndrome. One part of the study will investigate whether a combination of and can improve patient outcomes compared to the usual care. is a substance that can help regulate heart rhythm, while is a medication that helps prevent blood clots by keeping blood vessels open.

Another part of the study will examine if , a medication that helps prevent blood clots, can reduce the risk of clot-related events such as strokes or heart attacks in patients with . Participants in this study will be randomly assigned to receive either the study medications or a placebo, which is a substance with no active ingredients. The study will monitor participants over a period of up to 30 days to assess the effects of the treatments on heart function and the occurrence of any heart-related events.

The goal of this research is to determine if these treatments can provide better outcomes for patients with by improving heart function and reducing the risk of complications. Participants will undergo regular check-ups and assessments to track their progress and ensure their safety throughout the study. The findings from this trial could help improve the management and treatment of this condition in the future.

]]>